|
1
|
Little EG and Eide MJ: Update on the
current state of melanoma incidence. Dermatol Clin. 30:355–361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quintanilla-Dieck MJ and Bichakjian CK:
Management of early-stage melanoma. Facial Plast Surg Clin North
Am. 27:35–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guy GP Jr, Thomas CC, Thompson T, Watson
M, Massetti GM and Richardson LC; Centers for Disease Control and
Prevention (CDC), : Vital signs: Melanoma incidence and mortality
trends and projections-United States, 1982–2030. MMWR Morb Mortal
Wkly Rep. 64:591–596. 2015.PubMed/NCBI
|
|
4
|
Duffy KL, Truong A, Bowen GM, Andtbacka
RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell
SR, et al: Adequacy of 5-mm surgical excision margins for
non-lentiginous melanoma in situ. J Am Acad Dermatol. 71:835–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nadiminti H, Scope A, Marghoob AA, Busam K
and Nehal KS: Use of reflectance confocal microscopy to monitor
response of lentigo maligna to nonsurgical treatment. Dermatol
Surg. 36:177–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nurse P, Masui Y and Hartwell L:
Understanding the cell cycle. Nat Med. 4:1103–1106. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hunt T, Nasmyth K and Novák B: The cell
cycle. Philos Trans R Soc Lond B Biol Sci. 366:3494–3497. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M: Physiological relevance of
cell cycle kinases. Physiol Rev. 91:973–1007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hunt T: Nobel Lecture. Protein synthesis,
proteolysis, and cell cycle transitions. Biosci Rep. 22:465–486.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merrick KA, Wohlbold L, Zhang C, Allen JJ,
Horiuchi D, Huskey NE, Goga A, Shokat KM and Fisher RP: Switching
Cdk2 on or off with small molecules to reveal requirements in human
cell proliferation. Mol Cell. 42:624–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guadagno TM and Newport JW: Cdk2 kinase is
required for entry into mitosis as a positive regulator of
Cdc2-cyclin B kinase activity. Cell. 84:73–82. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCurdy SR, Pacal M, Ahmad M and Bremner
R: A CDK2 activity signature predicts outcome in CDK2-low cancers.
Oncogene. 36:2491–2502. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chohan TA, Qian H, Pan Y and Chen JZ:
Cyclin-dependent kinase-2 as a target for cancer therapy: Progress
in the development of CDK2 inhibitors as anti-cancer agents. Curr
Med Chem. 22:237–263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tetsu O and McCormick F: Proliferation of
cancer cells despite CDK2 inhibition. Cancer Cell. 3:233–245. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hochegger H, Dejsuphong D, Sonoda E,
Saberi A, Rajendra E, Kirk J, Hunt T and Takeda S: An essential
role for Cdk1 in S phase control is revealed via chemical genetics
in vertebrate cells. J Cell Biol. 178:257–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berthet C, Aleem E, Coppola V, Tessarollo
L and Kaldis P: Cdk2 knockout mice are viable. Curr Biol.
13:1775–1785. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Enders GH: Mammalian interphase cdks:
Dispensable master regulators of the cell cycle. Genes Cancer.
3:614–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adelmann CH, Wang T, Sabatini DM and
Lander ES: Genome-wide CRISPR/Cas9 screening for identification of
cancer genes in cell lines. Methods Mol Biol. 1907:125–136. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Slipek NJ, Varshney J and Largaespada DA:
CRISPR/Cas9-based positive screens for cancer-related traits.
Methods Mol Biol. 1907:137–144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu HG, Liu Z, Jiang Y, Xiao JR, Li HY, Li
Z, Huo SS and Yu YJ: Apoptosis of human melanoma A375 cells induced
by lentivirus mediated CDK2-shRNA. Chin J Gerontol. 35:6345–6347.
2015.(In Chinese).
|
|
21
|
Liu HG, Liu Z, Jiang Y, Xiao JR, Li HY, Li
Z, Huo SS and Yu YJ: Apoptosis of human melanoma A375 cells induced
by adenovirus-associated virus mediated CDK2-shRNA. Chin J Control
Endemic Dis. 30:135–136. 2015.(In Chinese).
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Zhou F, Wang H, Lin D, Chen G, Zuo
X, Sun L, Zhang X and Yang S: Knockdown of myosin VI by
lentivirus-mediated short hairpin RNA suppresses proliferation of
melanoma. Mol Med Rep. 12:6801–6806. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song Z, Lin J, Sun Z, Ni J and Sha Y:
RNAi-mediated downregulation of CDKL1 inhibits growth and
colony-formation ability, promotes apoptosis of human melanoma
cells. J Dermatol Sci. 79:57–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang YQ, Pei JH, Shi SS, Guo XS, Cui GY,
Li YF, Zhang HP and Hu WQ: CRISPR/Cas9-mediated knockout of the
PDEF gene inhibits migration and invasion of human gastric cancer
AGS cells. Biomed Pharmacother. 111:76–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao S, He Z and Chen C:
CRISPR/Cas9-mediated genome editing of epigenetic factors for
cancer therapy. Hum Gene Ther. 26:463–471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhen S and Li X: Oncogenic human
papillomavirus: Application of CRISPR/Cas9 therapeutic strategies
for cervical cancer. Cell Physiol Biochem. 44:2455–2466. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Biagioni A, Laurenzana A, Margheri F,
Chilla A, Fibbi G and So M: Delivery systems of CRISPR/Cas9-based
cancer gene therapy. J Biol Eng. 12:332018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martín A, Odajima J, Hunt SL, Dubus P,
Ortega S, Malumbres M and Barbacid M: Cdk2 is dispensable for cell
cycle inhibition and tumor suppression mediated by p27(Kip1) and
p21(Cip1). Cancer Cell. 7:591–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng C, Zeng W, Su J, Kuang Y, He Y, Zhao
S, Zhang J, Ma W, Bode AM, Dong Z and Chen X: Cyclin-dependent
kinase 2 (CDK2) is a key mediator for EGF-induced cell
transformation mediated through the ELK4/c-Fos signaling pathway.
Oncogene. 35:1170–1179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bacevic K, Lossaint G, Achour TN, Georget
V, Fisher D and Dulic V: Cdk2 strengthens the intra-S checkpoint
and counteracts cell cycle exit induced by DNA damage. Sci Rep.
7:134292017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shalem O, Sanjana NE, Hartenian E, Shi X,
Scott DA, Mikkelson T, Heckl D, Ebert BL, Root DE, Doench JG and
Zhang F: Genome-scale CRISPR-Cas9 knockout screening in human
cells. Science. 343:84–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koike-Yusa H, Li Y, Tan EP,
Velasco-Herrera MC and Yusa K: Genome-wide recessive genetic
screening in mammalian cells with a lentiviral CRISPR-guide RNA
library. Nat Biotechnol. 32:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kale J, Osterlund EJ and Andrews DW: BCL-2
family proteins: Changing partners in the dance towards death. Cell
Death Differ. 25:65–80. 2018. View Article : Google Scholar
|
|
35
|
Adams JM and Cory S: The BCL-2 arbiters of
apoptosis and their growing role as cancer targets. Cell Death
Differ. 25:27–36. 2018. View Article : Google Scholar
|
